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Background: The prognosis of acute lung injury (ALI) after pneumonectomy is poor, with reported mortality rates
of 30-100%. Neutrophil elastase inhibitor (NEI) is known to prevent lung injury caused by neutrophil elastase and
improve lung function in ALI. We evaluated the effect of NEI on ALI after pneumonectomy.
Methods: We analyzed nine patients who required ventilator care due to ALI after pneumonectomy. Five of these
patients underwent conventional ventilator care (group I), and four patients underwent ventilator care and were
administrated NEI (group II). We retrospectively analyzed the lung injury score (LIS) for 10 days after intubation.
Results: The LIS before intubation satisfied the diagnostic criteria of ALI or acute respiratory distress syndrome
(ARDS) in all patients. After intubation, the LIS improved in both groups. But, as times went on, the mean value of
the LIS in group II was lower compared to group I. In group I, only one patient underwent extubation. In group II,
extubation was possible in three patients. Mortality rates were 80% in group I and 25% in group II.
Conclusions: We conclude that NEI may improve the lung function, shorten the duration of mechanical ventilation,
and reduce mortality in patients with ALI after pneumonectomy.Background
Acute lung injury (ALI) after lung resection may be due
to systemic inflammatory reactions syndrome or lymph-
atic drainage dysfunction [1]. The incidence of ALI after
pneumonectomy is 2–5 times higher than the incidence
after lobectomy [2]. Furthermore, the prognosis of ALI
after pneumonectomy is considerably poor, with reported
mortality rates of 30-100% [3]. Therefore, a substantial
amount of effort has been focused on increasing the sur-
vival rate of ALI after pneumonectomy [4].
Recently, several studies have reported that sivelestat, a
new neutrophil elastase inhibitor (NEI) drug, prevents
lung injury caused by neutrophil elastase and improves
the lung function in ALI [5,6]. Sivelestat is also known to
shorten the duration of mechanical ventilation and reduce
mortality of ALI. However, there are only a few clinical
reports investigating whether NEI has positive effects on* Correspondence: yumccs@nate.com
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reproduction in any medium, provided the orALI after pneumonectomy. In this study, we evaluate the
effects of sivelestat on ALI after pneumonectomy.
Methods
From April 2004 to December 2010, nine patients re-
quired ventilator care due to ALI after pneumonectomy.
We retrospectively reviewed the medical records. Table 1
shows the characteristics of the patients. We used
sivelestat (ElaspolW, ONO Pharmaceutical Co., Osaka,
Japan) in the treatment of acute lung injury or acute re-
spiratory failure since September 2006. We classified two
groups according to using of suvekestat. Five of these pa-
tients underwent conventional ventilator care only, and
these were defined as group I. Four patients received ven-
tilator care and were administered sivelestat. This patient
group was defined as group II. Sivelestat was adminis-
trated immediately after intubation and was continuously
infused at rate of 0.2 mg/kg/h for 10 days. There was no
difference of treatment policy except sivelestat between
two groups.
We used Murray’s acute lung injury score (LIS) to as-
sess the extent of lung injury [7]. This scoring system. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics
Number Sex Age Cause Pneumonectomy side NEI Extubation Survival Onset of ALI (POD)
1 Male 45 Pneumonia Right No Yes Yes 4
2 Male 55 Aspiration Right No No No 147
3 Male 42 Pneumonia Right No Yes* No 204
4 Male 67 Pneumonia Right No No No 91
5 Male 77 Pulmonary edema Left No No No 1
6 Male 66 Pneumonia Left Yes Yes Yes 36
7 Male 63 Pneumonia Left Yes Yes Yes 9
8 Male 68 Pneumonia Left Yes No No 26
9 Male 54 Aspiration Right Yes Yes Yes 6
*Reintubation after extubation.
NEI, neutrophil elastase inhibitor; ALI, acute lung injury; POD, postoperative day.
Table 2 Lung injury score (Murray score)
1. Chest roentgenogram score
No alveolar consolidation 0
Alveolar consolidation confined to 1 quadrant 1
Alveolar consolidation confined to 2 quadrant 2
Alveolar consolidation confined to 3 quadrant 3







3.PEEP score (when ventilated)
PEEP ≤5 cm H2O 0
PEEP 6-8 cm H2O 1
PEEP 9-11 cm H2O 2
PEEP 12-14 cm H2O 3
PEEP ≥15 cm H2O 4
4. Respiratory system compliance score (when available)
Compliance ≥80 ml/cmH2O 0
Compliance 60-79 ml/cmH2O 1
Compliance 40-59 ml/cmH2O 2
Compliance 20-39 ml/cmH2O 3
Compliance ≤19 ml/cmH2O 4
Score
No lung injury 0
Mild to moderate lung injury 0.1-2.5
Severe lung injury (ARDS) >2.5
PaO2/FiO2, arterial oxygen tension to inspired oxygen concentration ratio;
PEEP, positive end-expiratory pressure; ARDS, acute respiratory
distress syndrome.
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positive end expiratory pressure (PEEP) score, and re-
spiratory system compliance score (Table 2). The final
value is obtained by dividing the aggregate sum by the
number of components that were used. We calculated the
LIS at the time of pre-intubation, post-intubation, and
every day for 10 days following post-intubation. When
the final value of the LIS was less than 0.5, patients were
weaned off the ventilator. All values are reported as mean
± standard deviation. Prior to data collection, we obtained
approval from the ethics committee of Eulji University
Hospital. Informed consent was obtained from the patient
or families for publication.
Results
The LIS before intubation was 3.0±0.0 in group I and
3.0±0.0 in group II. These values before intubation satis-
fied the diagnostic criteria of ALI or acute respiratory
distress syndrome (ARDS) in all patients. The mean
value of the LIS after intubation and mechanical ventila-
tion rapidly decreased to 2.3±0.2 (range = 2.0-2.7) in
group I and 2.5±0.1 (range = 2.3-2.7) in group II. The
mean value of the LIS on post-intubation day 1 further
improved to 1.5±0.7 (range = 0.7-2.3) in group I and 1.4
±0.6 (range = 0.7-2.0) in group II. Improvements in the
LIS appeared in both groups regardless of the use of
sivelestat.
The mean value of LIS in group II continued to de-
crease with time when compared with the LIS of group I
(Figure 1). In group I, only two patients (40%) achieved
an LIS less than 0.5, the score consider low enough to
wean the patient off the mechanical ventilator. These
two patients achieved this score after 7 and 10 days of
ventilator care, respectively. Only one of these two pa-
tients was able to undergo extubation. The other patient
required re-intubation due to immediate deterioration of
respiratory function after extubation, and he could not
be weaned off the ventilator thereafter. In contrast to
group 1, in group II three patients (75%) achieved an
Figure 1 Changes in lung injury score from the onset of ALI to 10 days after intubation.
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were successfully weaned off the ventilator. Only one pa-
tient in this group (who suffer from an acute myocardial
infarction) did not achieve an LIS of 0.5 or less.
All patients who failed in being weaned off the ventila-
tor died. The overall mortality rate was 80% in group I
and 25% in group II. All deaths (n=4) in group I were re-
lated to respiratory failure. In group II, the only death
was due to acute myocardial infarction. This patient’s
value of arterial oxygen tension to inspired oxygen con-
centration ratio (PaO2/FiO2) was 302.2 mmHg.
Discussion
ALI is caused by neutrophils which are activated by sys-
temic inflammatory reactions. Activated neutrophils mi-
grate to the lung and secrete elastase which induces the
secondary migration of neutrophils. This process dam-
ages vascular endothelial or pulmonary epithelial cells,
which accelerates the lung damage [8].
Several animal studies have reported that NEI can in-
hibit the elastase-dependent migration of neutrophils
and the production of cytokines [9,10]. Therefore, NEI is
expected to attenuate the progression of ALI [11]. NEI
has already been used clinically for treating ALI [12].
However, it still remains controversial whether NEI has
positive effects on all types of ALI. Zeiher et al. [13]
reported that NEI did not significantly affect mortality rate
or ventilator free day. Bernard et al. [14] also reported that
NEI did not significantly alter the mortality of ARDS.
Because patients who have undergone pneumonectomy
have lower pulmonary function, ALI after pneumonec-
tomy seems to show specific pattern of clinical progress
when compared to different types of ALI. First, patients
with ALI after pneumonectomy generally have severe re-
spiratory symptoms, with a PaO2/FiO2 less than 100 at
the time of diagnosis. Second, the symptoms occur early
in comparison with the real degree of ALI progression.
Third, the values of PaO2/FiO2 are recovered immediatelyafter mechanical ventilation. We see this in the patients in
our study. These patients had a mean value of more than
250 mmHg on post-intubation day 2.
Considering the pharmacokinetics of NEI, NEI should
be used in the early stage of ALI to maximize the cura-
tive effects. Hoshi et al. [6] reported that the use of NEI
in the early stage of ALI could shorten the duration of
mechanical ventilation and reduce mortality. However,
in cases of severe ALI where many neutrophils have
already migrated to the lung and induced alveolar dam-
ages, NEI was unable to significantly improve symptoms.
The symptoms of ALI after pneumonectomy are severe.
However, such severe symptoms may help provide an
early diagnosis and proper course of treatment. There-
fore, administering NEI along with mechanical ventila-
tion upon observed declined lung functions in ALI after
pneumonectomy has allowed for the rapid recovery of
lung function.
It generally takes a long time to fully recover lung
function up to the pre-ALI level, and prolonged mech-
anical ventilation causes ventilator-induced secondary
lung injuries. Since NEI is able to shorten the duration
of ventilation, we speculate it could also reduce the inci-
dence of ventilator-induced lung injury which may re-
duce the incidence of complications in pneumonectomy
patients.
Conclusions
In summary, patients who were administered NEI along
with mechanical ventilation after pneumonectomy had a
lower LIS, a shorter duration of ventilation, and a higher
success rate of ventilator weaning compared to patients
who received only ventilator therapy. Treatment with NEI
also resulted in lower overall mortality. This study has im-
portant limitations including a small subject number and
retrospective analysis. However, our data indicate that NEI
treatment leads to improved the lung function in early
ALI patients and warrants further investigation.
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